Oxford Cannabinoid Technologies to Initiate First-In-Human Clinical Trial for Cannabinoid CB2 Receptor Agonist AAT-730 in the United Kingdom


Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO:Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Wales Research Ethics Committee 2 (REC 2) have approved the combined Phase I clinical trial application for AAT-730 (OCT461201).  Accordingly, OCT will commence a participant enrolment in this First-In-Human (FIH) clinical trial for AAT‑730 in the United Kingdom immediately, and then plans to complete during Q3 2023. 


For more information, please refer to OCT’s Press Release in below:


About OCT:

OCT is a biopharmaceutical venture company established to combine cannabinoid medicine with world-class scientific research.  In 2019, AskAt announced an agreement of worldwide licensing (except for Japan) for AAT-730 in human use with OCT.  OCT debuted on the Main Market of the LSEG (London Stock Exchange Group) in May 2021.  Please refer to the company’s web page for details (


About cannabinoid CB2 Receptor Agonist AAT-730:

Cannabinoid receptors are a traditional drug target for pain and neurological disease therapy.  Recent scientific research on cannabinoids has revealed the potential of the CB2 receptor, one of two cannabinoid receptors, as a molecular target for neuropathic pain, cancer pain, neurodegenerative disease, such as Alzheimer’s and Parkinson’s diseases, neuroinflammatory diseases, cancer, and diabetes.  CB1 and CB2 each have different distribution profiles and pharmacological functions in the human body.  A number of pharmaceutical companies have attempted to develop CB2-selective agonists without CB1-mediated neurological side effects, however without success.  AskAt is developing AAT-730, a small molecule and highly selective CB2 agonist, with no CB1-related untoward effects, and potent CB2-mediated pharmacological efficacy in in vivo studies.  AAT-730 has shown potential as an effective therapy for Chemotherapy Induced Peripheral neuropathy (CIPN), which is OCT’s primary target indication of their forthcoming clinical development.